The reverse split is a mechanical adjustment to maintain Nasdaq listing compliance and does not change the company's fundamental value. Monitor for any subsequent equity offering or business development updates that could affect the post-split share price.
SCYX drugs
SCYX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 26 $5.45entry
- T+1 · 6mo ago +2.92%α +2.91% · $5.61
- T+5 · 6mo ago −2.17%α −3.25% · $5.33
- T+20 · 5mo ago −29.83%α −27.88% · $3.82
- T+60 · 3mo ago −5.47%α −8.19% · $5.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SCYNEXIS shareholders approved a reverse stock split at a special meeting on May 19, 2026, with 44.8M votes for and 6.7M against. The Board subsequently set the ratio at 1-for-8, effective May 29, 2026, reducing authorized shares from 150M to 18.75M. This is a routine capital structure adjustment to maintain Nasdaq listing compliance, with no fundamental business impact.
Key Facts
- Shareholders approved reverse stock split at a ratio between 1:5 and 1:10 at a special meeting on May 19, 2026
- Board set the specific ratio at 1-for-8 on May 19, 2026
- Reverse stock split effective May 29, 2026; split-adjusted trading begins June 1, 2026
- Authorized shares reduced from 150,000,000 to 18,750,000
- No fractional shares will be issued; cash paid in lieu of fractional shares
- Ticker symbol SCYX unchanged; new CUSIP is 811292 309
Financial Impact
No direct financial impact; authorized shares reduced from 150M to 18.75M via 1:8 reverse split. Proportional ownership unchanged except for fractional share cash-outs.
Risk Factors
- Post-split stock may face selling pressure from retail holders cashing out fractional shares
- Reverse splits are often viewed negatively by the market as a sign of distress, though this is a routine compliance action
- Reduced share count increases volatility on a per-share basis
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178253-26-000014 |
| Document: 0001178253-26-000014-index-headers.html | 0001178253-26-000014 |
| Document: 0001178253-26-000014-index.html | 0001178253-26-000014 |
| Document: 0001178253-26-000014.txt | 0001178253-26-000014 |
Track record
14 reports on SCYX
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +33.49% at T+20 after the May 11, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.91 Now $2.91 +0.00% settles Nov 24
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $3.81 to $3.86 Now $2.91 −23.62% ▲ +1.31% +0.61% vs SPY
- Oct 6, 20265w ago Press Release Neutral 4/10 Entry $4.84 to $3.99 Now $2.91 −39.88% ▼ −17.56% −17.42% vs SPY
- Sep 28, 20267w ago Press Release Bullish 6/10 Entry $4.62 to $5.03 Now $2.91 −37.01% ▲ +8.87% +7.67% vs SPY
- Sep 22, 20267w ago 8-K Neutral 2/10 Entry $4.86 to $4.66 Now $2.91 −40.12% ▼ −4.12% −2.93% vs SPY
- Sep 10, 20269w ago 8-K Neutral 2/10 Entry $4.70 to $4.45 Now $2.91 −38.09% ▼ −5.32% −4.82% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $3.87 to $4.73 Now $2.91 −24.81% ▲ +22.22% +20.83% vs SPY
- May 22, 202625w ago 8-K Neutral 4/10 Viewing Entry $5.45 to $5.33 Now $2.91 −46.59% ▼ −2.17% −3.25% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers